8-K: Sharps Technology Secures Five-Year Supply Agreement, Projecting Over $50 Million in Revenue

Sharps Technology has entered into a five-year supply agreement with Stericare Solutions, LLC for 520 million units of 10ml PP Sologard syringes, expected to generate over $50 million in revenue.

Summary

• Sharps Technology has signed a five-year supply agreement with Stericare Solutions, LLC to provide 520 million units of 10ml PP Sologard syringes.
• The agreement is expected to generate revenues in excess of $50 million.
• The supply will be phased, with 40 million units in the first year and 120 million units annually for the remaining four years.
• The agreement has an initial five-year term, automatically renewing for one-year periods unless terminated with 90 days' notice.
• The agreement can be terminated for material breach, insolvency, or acquisition by a competitor with varying notice periods.
• The agreement effectively sells out the current manufacturing capacity for the 10mL SoloGard syringe at Sharps' EU facility.
• Initial production will be from Sharps' Hungary facility, with potential for additional supply from facilities in Italy or the US.
• The agreement is expected to begin generating revenue in Q4 2024, with a phased ramp-up into 2025.

Sentiment

Score: 9

Explanation: The document conveys a very positive sentiment due to the significant supply agreement, expected revenue, and the sell-out of manufacturing capacity. The agreement is a major milestone for the company.

Positives

• The supply agreement is expected to generate significant revenue, exceeding $50 million.
• The agreement secures a long-term partnership with a strategic U.S. medical products company.
• The deal sells out the current manufacturing capacity of the EU facility, demonstrating strong demand for Sharps' products.
• The agreement provides a clear path for near-term revenue starting in Q4 2024.
• The agreement validates the quality and marketability of Sharps' SoloGard syringes.
• The agreement is expected to drive expansion of Sharps' manufacturing capacity.

Negatives

• The specific purchase price is confidential and redacted from the agreement.
• The agreement includes termination clauses that could potentially disrupt the supply relationship.
• The agreement is dependent on Sharps' ability to meet the required production volumes and timelines.
• The agreement is subject to potential price adjustments based on raw material cost fluctuations.

Risks

• The agreement could be terminated if either party breaches the terms, becomes insolvent, or is acquired by a competitor.
• Raw material price increases could impact profitability if not passed on to Stericare.
• There is a risk of production delays or quality issues that could affect the supply of syringes.
• The company's ability to expand manufacturing capacity to meet future demand is a potential challenge.
• The company is reliant on a single customer for the entire output of the EU facility.

Future Outlook

The company anticipates near-term revenue generation starting in Q4 2024, with a phased ramp-up into 2025, and expects the agreement to drive the need for near-term expansion of its manufacturing capacity.

Management Comments

• Robert Hayes, CEO of Sharps Technology, stated that the agreement is an historic accomplishment for Sharps and the future success of the Company.
• Filippo Filippi, General Manager of the SafeGard manufacturing facility, is pleased that his plant is delivering on commitments made by Sharps leadership in 2022.
• Filippo Filippi is excited for this five-year commitment for the 500 million units, starting with the 10mL SoloGard shipments in November of this year.

Industry Context

The agreement comes at a time when the U.S. healthcare industry is seeking alternatives to Chinese-manufactured disposable syringes due to recent FDA recalls and tariffs, positioning Sharps as a viable supplier of high-quality products.

Comparison to Industry Standards

• The agreement is a significant win for Sharps, securing a large volume order for its syringes.
• The 520 million unit order is substantial compared to typical medical device supply agreements.
• The five-year term provides long-term revenue visibility, which is favorable compared to shorter-term contracts.
• The agreement positions Sharps to compete with established players in the syringe market, such as Becton Dickinson and Medtronic, by offering a high-quality alternative to Chinese-manufactured products.
• The agreement is similar in scope to large-scale supply agreements between pharmaceutical companies and medical device manufacturers, such as those seen in the vaccine and biologics sectors.

Stakeholder Impact

• Shareholders will benefit from the expected revenue growth and increased market presence.
• Employees may see increased job security and potential for growth.
• Customers will have access to a reliable supply of high-quality syringes.
• Suppliers may see increased demand for raw materials.
• Creditors may have increased confidence in the company's financial stability.

Next Steps

• Sharps will begin production of the 10ml PP Sologard syringes.
• The company will work towards the initial delivery of product targeted for November 1, 2024.
• Sharps will need to expand its manufacturing capacity to meet the demand of the agreement.
• The company will continue to explore opportunities to expand its market presence and product offerings.

Key Dates

Keywords

supply agreement, syringes, medical devices, manufacturing, revenue, Stericare Solutions, SoloGard, Sharps Technology, healthcare, disposable syringes